FCE 28260

FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH) [1].

Product Specifications

CAS Number

[155651-56-2]

UNSPSC

12352005

Target

5 alpha Reductase

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Endocrinology

Smiles

C[C@@]12[C@](CC[C@@H]2C(NC(C)(C3=CC=CC=C3)C(F)(F)F)=O)([H])[C@@]4([H])[C@@](CC1)([H])[C@@]5([C@@](NC(C=C5)=O)([H])CC4)C

Molecular Formula

C28H35F3N2O2

Molecular Weight

488.58

References & Citations

[1]Giudici D, et al. FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects. J Steroid Biochem Mol Biol. 1996 Jun;58 (3) :299-305.